In this episode, Fidelia Bernice, PharmD, and Aadia I. Rana, MD, share insights on HIV ART safety and tolerability including recent data on nephrotoxicity and the use of NRTI-sparing regimens with discussion of the GEMINI-1 and -2 studies of DTG/3TC and the SWORD-1 and -2 studies of DTG/RPV, and safety with long-acting injectables with specific discussion of the ATLAS and FLAIR studies
Ursula Matulonis, MD
Program Director
Robert L. Coleman, MD, FACOG,
FACS
Angeles Alvarez Secord, MD,
MHSc
David Scott Miller, MD,
FACS
Prof Isabelle Ray-Coquard, MD,
PhD
In this commentary, Daniel A. Pollyea, MD, MS, provides his strategies for treating patients with myelodysplastic syndrome.
Released: September 24, 2021
In this commentary, Daniel A. Pollyea, MD, MS, provides his strategies for treating patients with myelodysplastic syndrome.
Released: September 24, 2021
In this commentary, Daniel A. Pollyea, MD, MS, provides his strategies for treating patients with myelodysplastic syndrome.
Released: September 24, 2021
Download this short summary slideset on myelodysplastic syndromes to help diagnose and manage your patients.
Released: September 24, 2021
Download this summary slideset from a live webinar for a quick overview of the evolving use of PARP inhibitors
Released: September 24, 2021
Watch this interactive webcast of a live CCO webinar to gain expert perspectives on individualizing treatment
Released: September 24, 2021
Provided by Clinical Care Options, LLC
For customer support please email
customersupport@cealliance.com
Clinical Care Options,
LLC 12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
Back to activities